Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 19/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 19/20 | 0.49 |
| ▸ | ITGAL | P20701 | 19/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18868515 | 0.85 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9L3MBTL1 | |
| SCHEMBL20903203 | 0.84 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL879313 | 0.84 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| Hydrochloric Acid SCHEMBL20680588 | 0.84 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| Hydrochloric Acid SCHEMBL20680587 | 0.84 | ITGB2 (0.65) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445327 | 0.80 | ITGB2 (0.46) | ITGB2ICAM1ITGALCYP2C9L3MBTL1 | |
| SCHEMBL19134123 | 0.80 | ITGB2 (0.42) | ITGB2ICAM1ITGALCYP2C9L3MBTL1 | |
| SCHEMBL13588336 | 0.78 | POLB (0.48) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445340 | 0.78 | ITGB2 (0.59) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19134129 | 0.77 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246862-B2 | Process for the preparation of lifitegrast | MANKIND PHARMA LTD. (IN) | 2022-02-15 | — | — | US | disclosed |
| US-20200306242-A1 | NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST | MANKIND PHARMA LTD. (IN) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246862-B2 | Process for the preparation of lifitegrast | LIFR, PTGFR, CSF1R | ITGB2 839/4885ICAM1 4016/4885ITGAL 527/4885 |
| US-20200306242-A1 | NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, CSF1R, CSF3R | ITGB2 764/4885ICAM1 3758/4885ITGAL 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.